The Experimental Therapeutics Institute serves as the interdisciplinary institutional platform for the development of new drugs, devices, and intellectual property that grow out of Mount Sinai’s basic and clinical research projects. This Institute provides a range of emerging and established technologies to Mount Sinai researchers that enable the translation of basic biological mechanisms into therapeutics. The services provided by the institute include high-throughput screening of chemical libraries, medicinal chemistry, pharmacokinetics and pharmacodynamics and computation and systems pharmacology. Currently the Center has members from nineteen basic and clinical departments across the institution.

The Experimental Therapeutics Institute is an important component of Mount Sinai Medical Center’s clinical and translational research activities. Utilizing funds from the Clinical and Translational Award from the NIH, the Experimental Therapeutics Institute competitively funds pilot project grants to foster cutting-edge translational research. The Institute also funds research fellowships to develop a new generation of clinical and translational researchers.

The Experimental Therapeutics Institute works closely with the Mount Sinai Office of Technology and Business Development to provide a seamless pipeline for the development of new drugs and therapies including the organization of joint activities such as seminars and workshops.  The Office of Technology and Business Development has an Innovation Fund that competitively funds projects   to enhance their near-term potential for commercialization. The Institute is supported by philanthropic funds and by funds by the NCRR CTSA award to Mount Sinai and NIGMS Systems Biology Center Grant.